Schizophrenia News and Research

Latest Schizophrenia News and Research

Adolescents diagnosed with schizophrenia appear to show greater brain GM volume loss

Adolescents diagnosed with schizophrenia and other psychoses appear to show greater decreases in gray matter volume and increases in cerebrospinal fluid in the frontal lobe compared to healthy adolescents without a diagnosis of psychosis, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Jan 2012

DNA stays too tightly wound in brain cells of patients with schizophrenia

Scientists at The Scripps Research Institute have discovered that DNA stays too tightly wound in certain brain cells of schizophrenic subjects. The findings suggest that drugs already in development for other diseases might eventually offer hope as a treatment for schizophrenia and related conditions in the elderly.

28 Dec 2011

Current scientific understanding of left and right-handedness

Left-handedness is sometimes the expression of a genetic defect or an early developmental disturbance. In this issue of Deutsches Ärzteblatt International, Stefan Gutwinski and coauthors present the current scientific understanding of left- and right-handedness.

28 Dec 2011

Neuroscientists discover gene responsible for HDLS

A global team of neuroscientists, led by researchers at Mayo Clinic in Florida, have found the gene responsible for a brain disorder that may be much more common than once believed. In the Dec. 25 online issue of Nature Genetics, the researchers say they identified 14 different mutations in the gene CSF1R that lead to development of hereditary diffuse leukoencephalopathy with spheroids.

26 Dec 2011

Biologists develop radar to track ADAR's RNA editing activity in neurons

To track what they can't see, pilots look to the green glow of the radar screen. Now biologists monitoring gene expression, individual variation, and disease have a glowing green indicator of their own: Brown University biologists have developed a "radar" for tracking ADAR, a crucial enzyme for editing RNA in the nervous system.

26 Dec 2011

N.Y. Times review finds misuse of psychotropic drugs in disabled patients

Tens of thousands of powerful pills created to treat serious mental illnesses like schizophrenia are given to developmentally disabled people in the care of New York State every day.

23 Dec 2011

Walgreen expecting sharp drop in prescription business

A contract dispute with pharmacy benefit manager Express Scripts is likely to cut the number of drugs Walgreen will sell.

23 Dec 2011

CNVs appear to play a significant role in early onset bipolar disorder

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, reports that abnormal sequences of DNA known as rare copy number variants, or CNVs, appear to play a significant role in the risk for early onset bipolar disorder.

22 Dec 2011

IRSF announces new grants for research into Rett syndrome

The International Rett Syndrome Foundation (IRSF) announced today that it is awarding over $1.5M to support 18 new grants designed to study a variety of diverse topics from basic science and disease pathology to developing treatments and outcome measures for Rett syndrome.

20 Dec 2011

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

Alkermes plc today announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia. ALKS 9070, a proprietary Alkermes molecule, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY for the treatment of a number of central nervous system disorders.

19 Dec 2011

Small genetic changes may increase risk of schizophrenia

Carrying single DNA letter changes from two different genes together may increase the risk of developing schizophrenia, Johns Hopkins researchers reported in the November 16 issue of Neuron.

15 Dec 2011

GW scientist to identify molecular mechanisms that define embryonic OE stem cells

Anthony-Samuel LaMantia, PhD, professor in the Department of Pharmacology and Physiology and Director of the GW Institute for Neuroscience in the School of Medicine and Health Sciences has been awarded a grant from the National Institutes of Health to identify molecular mechanisms that define embryonic olfactory epithelium (OE) stem cells.

14 Dec 2011

Positive results from Aestus' ATx08-001 Phase II study on post-herpetic neuralgia

Aestus Therapeutics, Inc. today reported positive results from a Phase II clinical study evaluating the efficacy of its novel neuropathic pain therapeutic, ATx08-001, in the treatment of post-herpetic neuralgia.

14 Dec 2011

Viewpoints: Obama's lessons from LBJ; Plan B positions; Choosing Gingrich

In 2005, for example, the United States devoted only 29 percent of gross domestic product to health and social services combined, while countries like Sweden, France, the Netherlands, Belgium and Denmark dedicated 33 percent to 38 percent of their G.D.P. to the combination.

9 Dec 2011

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.

9 Dec 2011

Considering varying extent to which genes are turned on or off can help develop personalised, predictive medicines

The vast majority of genetic disorders (schizophrenia or breast cancer, for example) have different effects in different people. Moreover, an individual carrying certain mutations can develop a disease, whereas another one with the same mutations may not. This holds true even when comparing two identical twins who have identical genomes. But why does the same mutation have different effects in different individuals?

8 Dec 2011

Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain

BioLineRx announced today the final results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic pain.

6 Dec 2011

Bold move by Astra Zeneca to share 22 early stage potential drugs with MRC

Drug maker AstraZeneca will be sharing 22 of its early-stage research compounds with the Medical Research Council as part of a make over of life sciences research. This would speed up patients’ access to breakthrough drugs and arrest the decline of research and development in the UK.

6 Dec 2011

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.

5 Dec 2011

Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.

5 Dec 2011

Schizophrenia News and Research

Latest Schizophrenia News and Research

Adolescents diagnosed with schizophrenia appear to show greater brain GM volume loss

DNA stays too tightly wound in brain cells of patients with schizophrenia

Current scientific understanding of left and right-handedness

Neuroscientists discover gene responsible for HDLS

Biologists develop radar to track ADAR's RNA editing activity in neurons

N.Y. Times review finds misuse of psychotropic drugs in disabled patients

Walgreen expecting sharp drop in prescription business

CNVs appear to play a significant role in early onset bipolar disorder

IRSF announces new grants for research into Rett syndrome

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

Small genetic changes may increase risk of schizophrenia

GW scientist to identify molecular mechanisms that define embryonic OE stem cells

Positive results from Aestus' ATx08-001 Phase II study on post-herpetic neuralgia

Viewpoints: Obama's lessons from LBJ; Plan B positions; Choosing Gingrich

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Considering varying extent to which genes are turned on or off can help develop personalised, predictive medicines

Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain

Bold move by Astra Zeneca to share 22 early stage potential drugs with MRC

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Schizophrenia News and Research

Latest Schizophrenia News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in